caa a22 4500 605490414 CHVBK 20210128100504.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0687-1 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0687-1 Clinical features of long-term survivors of recurrent epithelial ovarian cancer [Elektronische Daten] [Haruko Iwase, Toshio Takada, Chiaki Iitsuka, Hidetaka Nomura, Akiko Abe, Tomoko Taniguchi, Kimihiko Sakamoto, Ken Takizawa, Nobuhiro Takeshima] Background: Although recurrent epithelial ovarian cancer (EOC) is generally regarded as an incurable disease, some patients survive more than 5years after the first recurrence. The aim of this study was to evaluate the clinical features of patients with recurrent EOC who achieve long-term survival. Methods: We retrospectively reviewed the medical records of 164 patients with recurrent EOC and analyzed the clinical stage, histologic subtype, primary treatment, disease-free interval (DFI), recurrence site, secondary treatment, and overall survival from the time of the first recurrence (R-OS), using the Kaplan-Meier method and the log-rank test. Results: The median R-OS for all 164 patients was 25months and the 5-year R-OS rate was 25.4%. There were no significant differences in R-OS according to the disease stage. The median R-OS was significantly shorter in the 6-12-month DFI group (23months) than in the ≥12-month DFI group (61months) (p=0.0002), while there was no significant difference between the 6-12 and 3-6-month DFI groups (20months) (p=0.161). Of the 164 patients, only 14 survived >5years after the first recurrence. Most of them underwent surgery and/or radiotherapy in combination with chemotherapy and underwent >18 cycles of platinum-based chemotherapy throughout their treatments (median 22 cycles; range 4-44). Conclusions: If high sensitivity to platinum is maintained, patients with recurrent EOC may have prolonged survival following repeated platinum-based chemotherapy cycles. Moreover, their prognosis improves when chemotherapy is combined with secondary cytoreductive surgery and/or irradiation. Japan Society of Clinical Oncology, 2014 Recurrent epithelial ovarian cancer nationallicence Platinum-sensitivity nationallicence Disease-free interval nationallicence Long-term survival nationallicence Iwase Haruko Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut Takada Toshio Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut Iitsuka Chiaki Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut Nomura Hidetaka Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut Abe Akiko Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut Taniguchi Tomoko Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut Sakamoto Kimihiko Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut Takizawa Ken Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut Takeshima Nobuhiro Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 143-149 1341-9625 20:1<143 2015 20 10147 https://doi.org/10.1007/s10147-014-0687-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0687-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Iwase Haruko Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Takada Toshio Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Iitsuka Chiaki Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Nomura Hidetaka Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Abe Akiko Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Taniguchi Tomoko Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Sakamoto Kimihiko Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Takizawa Ken Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Takeshima Nobuhiro Department of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 143-149 1341-9625 20:1<143 2015 20 10147